Home » India Gives FDC Makers 90 Days to Justify Product Safety, Efficacy

India Gives FDC Makers 90 Days to Justify Product Safety, Efficacy

November 16, 2016

Pharmaceuticals Regulatory Affairs

India is giving drugmakers of unapproved combination products more time to justify their manufacturing and marketing of the drug in the country.

To View This Article:

Login

21Apr
CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health
26Apr
MAGI's Clinical Research vConference — Spring 2021
06May
The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next
12May
Extractables and Leachables: 101
25May
How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

Featured Stories

The Revised ICH E8: A Guide to New Clinical Trial Requirements